Biomarkers Used in the Diagnosis of Hyper-Inflammation of COVID-19

biyomedikalozel5-1-24kapak

Tanıl KOCAGÖZa,b
aAcıbadem Mehmet Ali Aydınlar University Faculty of Medicine, Department of Medical Microbiology, İstanbul, Türkiye
bAcıbadem Mehmet Ali Aydınlar University Health Sciences Institute, Head of the Department of Medical Biotechnology, İstanbul, Türkiye

Kocagöz T. Biomarkers used in the diagnosis of hyper-inflammation of COVID-19. In: Koçdor H, Pabuççuoğlu A, Zihnioğlu F, eds. Inflammation and in vitro Diagnostics. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.176-9.

Article Language: EN

ABSTRACT
Coronavirus-2019 (COVID-19) caused a serious pandemic and killed millions of people. It is expected to have more epidemics in the future due to the ability of rapid mutation of SARS-COV-2 which creates new variants. After the infection starts usually immune response eliminates the virus. However, in some people there is an exaggerated immune-response which leads to hyper-inflammation. This causes more damage in tissues, especially in blood vessels. In extreme cases, disseminated intravascular coagulation occurs and becomes the most important cause of death. Therefore, early diagnosis of hyperinflammation is very important for timely hospitalization of patients and hyper-inflammation prevention and treatment. This can be achieved by closely monitoring hyper-inflammation biomarkers. It has been shown that lymphopenia, high levels of Interleukin 6, TNF, Interferon I, D-dimer, lactate dehydrogenase, creatinine, cardiac troponin I and myoglobin, prolonged prothrombin and activated partial thromboplastin time are important indicators of hyper-inflammation in COVID-19.

Keywords: COVID-19; inflammation; biomarkers

Referanslar

  1. Lee KS, Eom JK. Systematic literature review on impacts of COVID-19 pandemic and corresponding measures on mobility. Transportation (Amst). 2023:1-55. [Crossref]
  2. Perlman S. COVID-19 poses a riddle for the immune system. Nature. 2020;584(7821):345-6. [Crossref]  [PubMed]
  3. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. Immunity. 2020;53(1):19-25. [Crossref]  [PubMed]  [PMC]
  4. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529-39. [Crossref]  [PubMed]  [PMC]
  5. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255-73. [Crossref]  [PubMed]  [PMC]
  6. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, Tet al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-81.e7. [Crossref]  [PubMed]  [PMC]
  7. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020;183(4):996-1012.e19. [Crossref]  [PubMed]  [PMC]
  8. Hope JL, Bradley LM. Lessons in antiviral immunity. Science. 2021;371 (6528):464-5. [Crossref]  [PubMed]
  9. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355-62. [Crossref]  [PubMed]  [PMC]
  10. Wang Y, Perlman S. COVID-19: Inflammatory Profile. Annu Rev Med. 2022; 73:65-80. [Crossref]  [PubMed]
  11. Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol. 2020;108(1):17-41. [Crossref]  [PubMed]  [PMC]
  12. Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019;10:1057. [Crossref]  [PubMed]  [PMC]
  13. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636-43. [Crossref]  [PubMed]  [PMC]
  14. Chen LYC, Hoiland RL, Stukas S, Wellington CL, Sekhon MS. Assessing the importance of interleukin-6 in COVID-19. Lancet Respir Med. 2021;9(2):e13. [Crossref]  [PubMed]
  15. Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. Front Immunol. 2021;12: 613422. [Crossref]  [PubMed]  [PMC]
  16. Zhang J, Hao Y, Ou W, Ming F, Liang G, Qian Y, et al. Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study. J Transl Med. 2020;18(1):406. [Crossref]
  17. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603-e12. [Crossref]  [PubMed]
  18. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395(10234):1407-9. [Crossref]  [PubMed]
  19. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol. 2012;2(3):264-75. [Crossref]  [PubMed]  [PMC]
  20. Miorin L, Kehrer T, Sanchez-Aparicio MT, Zhang K, Cohen P, Patel RS, et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc Natl Acad Sci U S A. 2020;117(45):28344-54. [Crossref]  [PubMed]  [PMC]
  21. Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, et al. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074. [Crossref]  [PubMed]  [PMC]
  22. Quarleri J, Delpino MV. Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors. Cytokine Growth Factor Rev. 2021;58:55-65. [Crossref]  [PubMed]  [PMC]
  23. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-24. [Crossref]  [PubMed]  [PMC]
  24. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, et al. Canadian SARS Research Network; Kelvin DJ. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007;81(16):8692-706. [Crossref]  [PubMed]  [PMC]
  25. Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19(2):181-93. [Crossref]  [PubMed]  [PMC]
  26. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113(1):45-57. [Crossref]  [PubMed]  [PMC]
  27. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-e47. [Crossref]  [PubMed]
  28. Kaufmann CC, Ahmed A, Burger AL, Muthspiel M, Jäger B, Wojta J, et al. Biomarkers Associated with Cardiovascular Disease in COVID-19. Cells. 2022;11(6):922. [Crossref]  [PubMed]  [PMC]
  29. Wright DJM. Prevention of the cytokine storm in COVID-19. Lancet Infect Dis. 2021;21(1):25-6. [Crossref]  [PubMed]